LUPIN-CELECOXIB CAPSULE
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
18-11-2014
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
CELECOXIB
Tilgængelig fra:
LUPIN PHARMA CANADA LIMITED
ATC-kode:
M01AH01
INN (International Name):
CELECOXIB
Dosering:
100MG
Lægemiddelform:
CAPSULE
Sammensætning:
CELECOXIB 100MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100/500
Recept type:
Prescription
Terapeutisk område:
CYCLOOXYGENASE-2 (COX-2) INHIBITORS
Produkt oversigt:
Active ingredient group (AIG) number: 0137043001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2014-11-17
Produktets egenskaber
_ _
_ _
_1 of 53 _
PRODUCT MONOGRAPH
PR
LUPIN-CELECOXIB
(celecoxib)
Capsules, 100 mg and 200 mg
Non-steroidal anti-inflammatory drug (NSAID)
Lupin Pharma Canada Limited
DATE OF PREPARATION:
1155, René-Lévesque West Blvd., Suite 2500 25 July 2014
Montreal QC,
H3B 2K4
SUBMISSION CONTROL NO: 154401, 175860
_ _
_ _
_2 of 53 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION.....................................................................3
INDICATIONS AND CLINICAL
USE...........................................................................3
CONTRAINDICATIONS
................................................................................................4
WARNINGS AND
PRECAUTIONS...............................................................................5
ADVERSE
REACTIONS................................................................................................14
DRUG
INTERACTIONS................................................................................................22
DOSAGE AND
ADMINISTRATION...........................................................................25
OVERDOSAGE...............................................................................................................27
ACTION AND CLINICAL
PHARMACOLOGY........................................................27
STORAGE AND
STABILITY.......................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL
INFORMATION.....................................................................31
CLINICAL
TRIALS.......................................................................................................32
DETAILED
PHARMACOLOGY.................................................................................40
Læs hele dokumentet
